Faculty of Medicine, Reproductive Endocrinology, Research Centre, Saint-Francis of Assisi Hospital, CHUQ, Laval University, Quebec, Canada.
Fertil Steril. 2011 Mar 15;95(4):1284-90. doi: 10.1016/j.fertnstert.2010.12.056. Epub 2011 Jan 26.
To investigate interleukin (IL) 1 receptor accessory protein (IL1RAcP) expression in the eutopic endometrium of women with endometriosis.
Retrospective study.
Human reproduction research laboratory.
PATIENT(S): Sixty-six women with endometriosis and 60 healthy women with no laparoscopic evidence of endometriosis.
INTERVENTION(S): Endometrial tissue samples were obtained during laparoscopic surgery.
MAIN OUTCOME MEASURE(S): IL1RAcP protein expression was analyzed by immunohistochemistry, Western blot, and ELISA, and IL1RAcP mRNA expression was analyzed by quantitative real-time polymerase chain reaction.
RESULT(S): This study showed a significant downregulation of soluble (s)IL1RAcP expression in the eutopic endometrium of women with endometriosis compared to normal women, occurring at the protein or mRNA level. This finding appeared to vary according to endometriosis stage, being more obvious in the earliest (I and II) than the latest (III and IV) stages of the disease. However, the membrane-bound IL1RAcP did not show any noticeable endometriosis-related change, neither at the protein or mRNA level.
CONCLUSION(S): In view of the wide spectrum of IL-1 inflammatory and growth-promoting effects, downregulation of sIL1RAcP, which is known for inhibiting IL1, indicates a profound defect in the capability of endometrial cells of women with endometriosis to counterregulate IL-1 effects and may represent an important mechanism underlying the ability of these cells to implant and develop into host tissues.
研究白细胞介素(IL)1 受体辅助蛋白(IL1RAcP)在子宫内膜异位症患者在位子宫内膜中的表达。
回顾性研究。
人类生殖研究实验室。
66 例子宫内膜异位症患者和 60 例无腹腔镜子宫内膜异位症证据的健康妇女。
腹腔镜手术中获取子宫内膜组织样本。
采用免疫组织化学、Western blot 和 ELISA 分析 IL1RAcP 蛋白表达,采用实时定量聚合酶链反应分析 IL1RAcP mRNA 表达。
本研究显示,与正常妇女相比,子宫内膜异位症患者在位子宫内膜中可溶性(s)IL1RAcP 表达显著下调,无论是在蛋白水平还是在 mRNA 水平均如此。这种发现似乎根据子宫内膜异位症的分期而有所不同,在疾病的最早(I 和 II 期)阶段比最晚(III 和 IV 期)阶段更为明显。然而,膜结合型 IL1RAcP 没有显示出任何与子宫内膜异位症相关的明显变化,无论是在蛋白水平还是在 mRNA 水平。
鉴于 IL-1 具有广泛的炎症和促进生长作用,sIL1RAcP 的下调表明子宫内膜异位症患者的子宫内膜细胞抑制 IL1 的能力存在严重缺陷,这可能是这些细胞能够植入和发展为宿主组织的重要机制。